MOH Appoints Fuwai Hospital As Quality Control Center On Cardiovascular Disease
This article was originally published in PharmAsia News
China's Ministry of Health has appointed the China Medical Science Academy's Fuwai Hospital as its quality control center on cardiovascular disease from June 1, 2009 through June 1, 2012. The hospital will conduct national quality control tasks of intervention treatment for congenital heart diseases and arrhythmia. The MOH will require Fuwai Hospital to collate, conduct statistical analysis and assess treatment cases reported by all localities, release half-yearly quality control reports and send feedback to medical care institutions. To be a qualified quality control center, it will add the necessary professionals and facilities, improve relevant rules and quality control structure, and map out workflow procedures. (Click here for more - Chinese Language)
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.